Aldosterone antagonism for HFpEF

Barry A. Borlaug

doi:10.1038/nrcardio.2013.51

Aldosterone antagonism for HFpEF

Barry A. Borlaug

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.

Original language	English (US)
Pages (from-to)	244-246
Number of pages	3
Journal	Nature Reviews Cardiology
Volume	10
Issue number	5
DOIs	https://doi.org/10.1038/nrcardio.2013.51
State	Published - May 2013

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1038/nrcardio.2013.51

Cite this

@article{55319b6bdfa0456baaed83c20f59d520,

title = "Aldosterone antagonism for HFpEF",

abstract = "No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.",

author = "Borlaug, {Barry A.}",

year = "2013",

month = may,

doi = "10.1038/nrcardio.2013.51",

language = "English (US)",

volume = "10",

pages = "244--246",

journal = "Nature Reviews Cardiology",

issn = "1759-5002",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Aldosterone antagonism for HFpEF

AU - Borlaug, Barry A.

PY - 2013/5

Y1 - 2013/5

N2 - No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.

AB - No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.

UR - http://www.scopus.com/inward/record.url?scp=84876938139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876938139&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2013.51

DO - 10.1038/nrcardio.2013.51

M3 - Review article

C2 - 23546445

AN - SCOPUS:84876938139

SN - 1759-5002

VL - 10

SP - 244

EP - 246

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

IS - 5

ER -

Aldosterone antagonism for HFpEF

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this